老年人由于身体机能的衰退以及慢性疾病的困扰，需要长期服用药物来控制疾病。心血管类药物则是老年人最常服用的一大类药。然而容易被忽略的是，在日常的饮食中，食物也有可能对药物产生影响，可以增强药效，也可能降低药效，甚至会引起不良反应。本文总结了不同的食物成 ...

Your body clears Xanax through a pathway known as cytochrome P450 3A (CYP3A). Medications that inhibit CYP3A4 make it harder for your body to break down Xanax, which increases your risk of overdosing.

卡博特韦/利匹韦林，商品名为Cabenuva ，是一种用于治疗艾滋病毒/艾滋病的联合包装抗逆转录病毒药物。它包含卡博特韦和利匹韦林，每个包装有两个独立的注射瓶。 这种联合包装药物于 2021 年 1 月在美国获批用于医疗。这是 FDA 批准的首个针对 ...

决奈达隆的商品名为Multaq ，是赛诺菲安万特公司开发的III 类抗心律失常药物。该药物于 2009 年 7 月获美国食品药品管理局 (FDA)批准。除了用于治疗心律失常外，它还被推荐作为胺碘酮的替代品，用于治疗心房颤动和心房扑动，适用于心脏已恢复正常节律或接受药物治疗或电击治疗，即直流电复律 (DCCV) 以维持正常节律的患者。

Eli Lilly and Company today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 66th American ...

Avoid coadministration of GAVRETO with strong or moderate CYP3A inhibitors, P-gp inhibitors, or combined P-gp and strong or moderate CYP3A inhibitors. If coadministration cannot be avoided ...

CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

FILSPARI ® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss ...

2023年10月26日，首个完整的HIV-1长效注射治疗方案：万凯锐 (卡替拉韦)和瑞卡必 (利匹韦林),获中国国家药品监督管理局 (NMPA) 批准。该方案每两个月注射一次，不用与口服 ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their ...